Evofem Biosciences Inc (EVFM) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Evofem Biosciences Inc $0.01, price $0.01, upside -17.1%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Evofem Biosciences Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $0.0060 – $2,063 · fair‑value band $0.0066 – $0.0070 · the $0.0082 price screens above the $0.0068 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Evofem Biosciences in your weekly email
Every Wednesday you see whether Evofem Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health.
Show more
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Stock analysis
Evofem Biosciences Inc (EVFM) currently trades at $0.0082, while our model-based Fair Value estimate is $0.0068, 17.1% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 12 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.0066 (bear) to $0.0070 (bull), the price of $0.0082 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Evofem Biosciences Inc reported revenue of $20.2M in FY2025 versus $8.2M in FY2021, a compound +25.1%/yr. Reported net income was $391K in FY2025.
Key figures
Market cap $1.2M · P/S ratio 0.06 · EPS (TTM) $−0.0500 · Dividend yield 9.8% · Net margin 1.9% · Return on equity −387% · Return on assets (EBIT) −184% · Operating margin −508%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 24 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and 37% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −17%, EVFM screens richer than that median.
Fair Value models
Bear $0.0066Fair Value $0.0068Bull $0.0070
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.45/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+114.4%
Start year 2020 (pandemic)
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+50.4%
’12
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−87.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−97.2%
Dividend (yield on the price)9.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−23,234% → 7%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside−8.1% · Above median
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−21.3% · Below median
Net margin (TTM)−29.8% · Below median
Growth and dividend
Revenue growth6.4% · Above median
Dividend yield (TTM)9.8% · Top 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)11· sector 0
FUTURE (revenue growth)32· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)100· sector 22
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Evofem Biosciences Inc (EVFM) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0068 versus a price of $0.0082, about −17% upside (overvalued).
What is the fair value of EVFM?
Our model-based fair value for Evofem Biosciences Inc is $0.0068 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.0082.
What is the quality score of EVFM?
Evofem Biosciences Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Evofem Biosciences Inc (EVFM)?
Our model-based price target is the fair value of $0.0068 (as of Sep 27, 2026) from 9 valuation models. Cautious scenario $0.0066, optimistic scenario $0.0070. It is a calculation from audited fundamentals, not an analyst target.
What is the Evofem Biosciences Inc stock forecast for 2026?
Our models put fair value at $0.0068, about −17% upside versus a price of $0.0082 (overvalued). Cautious scenario $0.0066, optimistic scenario $0.0070. The calculation is refreshed regularly with new filings.
What is the revenue of Evofem Biosciences Inc (EVFM)?
Evofem Biosciences Inc reported trailing-twelve-month revenue of about $20.2M (latest available figure, as of Sep 27, 2026).
Does Evofem Biosciences Inc pay a dividend?
Evofem Biosciences Inc currently shows a dividend yield of about 9.81% relative to its recent price (as of Sep 27, 2026).
What is the intrinsic value of Evofem Biosciences Inc (EVFM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Evofem Biosciences Inc it is $0.0068 per share (as of Sep 27, 2026), against a price of $0.0082. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Evofem Biosciences Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, EVFM trades above its calculated fair value: price $0.0082, fair value $0.0068, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EVFM?
No. The price is what the market pays today ($0.0082); the fair value is what the company's own numbers justify ($0.0068). For Evofem Biosciences Inc the two are $0.0014 per share apart. That gap is exactly why we show both numbers side by side.
How much is Evofem Biosciences Inc worth?
The market values Evofem Biosciences Inc at about $1.2M (market capitalisation, as of Sep 27, 2026). Per share that is $0.0082; our models calculate a fair value of $0.0068 per share.
What do the bullish and bearish scenarios say about EVFM?
Our models span a range for Evofem Biosciences Inc: cautious scenario $0.0066, base $0.0068, optimistic $0.0070 per share (as of Sep 27, 2026, price $0.0082). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Evofem Biosciences Inc (EVFM)?
Balance-sheet figures for Evofem Biosciences Inc (as of Sep 27, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is EVFM from its 52-week high?
Evofem Biosciences Inc trades at $0.0082, about 41% below its 52-week high of $0.0140 and 37% above the low of $0.0060 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0068 is for.
Which stocks are comparable to Evofem Biosciences Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Evofem Biosciences Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0082, calculated fair value $0.0068 (−17%), Quality Score 32/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EVFM calculated?
We run Evofem Biosciences Inc through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0068, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Evofem Biosciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Evofem Biosciences Inc (EVFM)?
The closing price on Oct 2, 2026 was $0.0082. Our model-based fair value is $0.0068, about −17% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Evofem Biosciences Inc right now?
The price sits above even our optimistic bull case ($0.0070). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band ($0.0066 to $0.0070), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Evofem Biosciences Inc
How large is the market capitalisation of Evofem Biosciences Inc (EVFM)?
The market capitalisation of Evofem Biosciences Inc is $1.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Evofem Biosciences Inc (EVFM)?
The price-to-sales ratio of Evofem Biosciences Inc is 0.06 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Evofem Biosciences Inc (EVFM)?
Earnings per share at Evofem Biosciences Inc are $−0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Evofem Biosciences Inc (EVFM)?
The dividend yield of Evofem Biosciences Inc is 9.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Evofem Biosciences Inc (EVFM)?
The net margin of Evofem Biosciences Inc is 1.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Evofem Biosciences Inc (EVFM)?
The return on equity (ROE) of Evofem Biosciences Inc is −387% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Evofem Biosciences Inc (EVFM)?
On an EBIT basis the return on assets of Evofem Biosciences Inc is −184% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Evofem Biosciences Inc (EVFM)?
The operating margin of Evofem Biosciences Inc is −508% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Evofem Biosciences Inc (EVFM)?
Revenue at Evofem Biosciences Inc is growing +6.4% versus a year earlier (3y avg +6.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Evofem Biosciences Inc (EVFM) generate?
The free cash flow of Evofem Biosciences Inc is −$2.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Evofem Biosciences Inc (EVFM) carry?
The net debt of Evofem Biosciences Inc is $54.0M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Evofem Biosciences Inc in the live analysis
One click puts Evofem Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026